Allfunds Group (ALLFG.AS) – Market Update and Regulatory Outlook
Allfunds Group traded 0.41 % higher during a 24‑hour period ending at 09:24 PM Central Europe on Friday, 23 November 2026. At the close, one share was priced at approximately EUR 9.78 on major exchanges. The company’s current supply of shares stands at 601.5 million, with a market capitalization of EUR 6.4 billion. In the last 24 hours, trading volume reached EUR 3.2 million. Since the close of the prior month, Allfunds has posted a 7.82 % gain. The simple moving average (SMA) over the last 200 days is EUR 8.66. The 52‑week high was EUR 9.90 on 19 October 2026, while the low was EUR 6.12 on 28 October 2025.
Regulatory Context
EU Antitrust Review
The European Commission is set to decide by late November whether to approve Deutsche Boerse’s acquisition of Allfunds Group. The transaction, valued at several billion euros, is central to Deutsche Boerse’s strategy of cementing its position as a key European financial infrastructure provider. Deutsche Boerse submitted a request for approval after a preliminary review, signalling that the regulator may approve the deal—with or without conditions—or launch a full investigation should significant competition concerns arise. The outcome will dictate whether the merged entity can operate under a unified regulatory framework across the European market. Allfunds Group’s continued role as a fund‑trading platform will hinge on the Commission’s assessment of the merger’s impact on market competition and investor access.
Recent Performance of Peer Stocks
| Ticker | 24‑hr Performance | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| IHS (4JB.F) | –0.12 % | USD 8.44 | USD 2.8 bn | 5.13 |
| HSBC (HSBA.L) | –2.29 % | GBX 1,352 | GBX 427.6 bn | 13.25 |
| TORM (1T4.F) | +6.68 % | EUR 35.1 | EUR 3.9 bn | 6.52 |
| AZN (AZN.L) | –0.03 % | GBX 12,824 | GBX 350.6 bn | 25.18 |
| KNSA | –4.17 % | USD 77.56 | USD 6.2 bn | 81.08 |
Additional Context
- HSBC launched the Hong Kong dollar‑backed stablecoin RedCoin for its PayMe wallet, expanding retail payment options and introducing tokenised investment subscriptions.
- TORM remains a relatively low‑profile target for short sellers, with a net short position just over 1 % of outstanding shares as of March 2026.
- AstraZeneca’s subsidiary Alexion received accelerated U.S. approval for Ultomiris, the first C5 complement inhibitor for primary immunoglobulin A nephropathy, following a positive interim analysis of the Phase III I CAN trial.
- Kiniksa Pharmaceuticals International will host a conference call on 27 October 2026 to discuss third‑quarter 2026 financial results and recent portfolio activities, focusing on cardiovascular indications and unmet‑needs therapies.
Forward‑Looking Perspective
Allfunds’ trajectory remains closely tied to the pending antitrust review. A favorable decision would accelerate integration with Deutsche Boerse’s platform, potentially unlocking efficiencies and expanding Allfunds’ reach across European markets. Conversely, a conditional approval or investigation could introduce regulatory delays and uncertainty. Investors should monitor the Commission’s timetable and any forthcoming conditions that may affect the transaction’s feasibility.
In the broader context, Allfunds’ performance relative to peers illustrates a resilient mid‑cap profile amid a volatile market landscape. While the 24‑hour volume remains modest, the upward trend since month‑end signals sustained investor confidence. The SMA anchor at EUR 8.66 and a recent high of EUR 9.90 suggest that the stock may continue to trade within a tightening range as market participants assess the merger’s implications.
